https://www.selleckchem.com/pr....oducts/alw-ii-41-27.
Regression was detected in the vascular lesions of 15 (71.4%) patients compared to the last image before bDMARD therapies. Our study results indicate that biological agents, such as INF and/or TCZ, that are used in the treatmentof TAK are capable of remedying certain vascular lesions and may provide additional benefits to patients with TAK who do not sufficiently respond to conventional synthetic disease-modifying antirheumatic drug (DMARD) treatment. Our study results indicate that biological agents, such as INF and/or TCZ, that a
Like
Comment
Share
